Asthma remedy

Article source Link, Article source Link,

'It was a very validating outcome.'
He said 120 patients participated in the first pilot study and 250 in the second.
The diabetics in the shared appointments had better blood pressure control, were more apt to be immunized appropriately and to follow up with eye and foot exams, and were better screened for kidney disease, he said.
'The outcomes were far better in shared appointments,' Millermaier said. 'Especially in the second study, we saw outcomes improve dramatically.'
Millermaier said he has found group appointments can also be helpful for people with asthma, prostate problems and erectile dysfunction as well as for people dealing with fatigue, weight issues or aging.
'The appointments are conducive to a shared learning environment,' he said. 'They learn from each other how to optimize their health.'
90 percent satisfaction
Currently, six doctors and other health-care providers in the Borgess Ambulatory System are offering shared medical appointments, five more Borgess doctors are planning to do so, and other physicians' offices have expressed interest, Millermaier said.
Doctors at Bronson Methodist Hospital do not offer group appointments, according to hospital spokesman Jason Manshum.
Borgess has found 90 percent patient satisfaction with the group appointments, Millermaier said

Also, two supporting six-month studies confirmed the efficacy of the drug when used with standard bronchodilator treatments.The Zurich-based firm said that full data from all four studies are expected to be published during 2009. It expects to file for European and US marketing authorisation next year and will initiate the process of identifying a partner to commercialise Daxas in the USA. Daxas is an orally administered phosphodiesterase 4 enzyme inhibitor, targeting cells and mediators in the body believed to be important in the COPD disease process. The firm says that if approved, Daxas, a once-a-day tablet, will be the first drug in its class and the first oral anti-inflammatory treatment for COPD patients. Hakan Bjorklund, Nycomeds chief executive, noting that the four Phase III trials involve more than 4,500 patients, will be a great addition to the firms product portfolio.' If Daxas gets the go-ahead, it would compete with the likes of Boehringer Ingelheim and Pfizers Spiriva (tiotropium) and GlaxoSmithKlines combination drug Advair/Seretide (salmeterol and fluticasone). AstraZeneca is hoping to get US approval soon for its asthma combo Symbicort (budesonide/formoterol) as a treatment for COPD.
By Kevin Grogan Latest forum comments

Blog Archives:
Laurey cabinet hardware

Custom cabinet design

Victorian cabinet

Asthma attack symptoms

Treatment for asthma

Clear glass tile

Amerock cabinet

Bathroom tile

Sachs mopeds

Tumbled marble tile

Dog tee shirt

Tile picture

Roketa moped

Limestone floor tiles

Treating asthma

New asthma guidelines

Towel warmer cabinet

Discount cabinet knobs